• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Evolving Landscape of Resistance to Osimertinib.

作者信息

Schoenfeld Adam J, Yu Helena A

机构信息

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.

出版信息

J Thorac Oncol. 2020 Jan;15(1):18-21. doi: 10.1016/j.jtho.2019.11.005.

DOI:10.1016/j.jtho.2019.11.005
PMID:31864549
Abstract
摘要

相似文献

1
The Evolving Landscape of Resistance to Osimertinib.奥希替尼耐药性的不断演变态势
J Thorac Oncol. 2020 Jan;15(1):18-21. doi: 10.1016/j.jtho.2019.11.005.
2
Overcoming resistance to osimertinib in non-small cell lung cancer: Hopes, doubts, and in-between.克服非小细胞肺癌对奥希替尼的耐药性：希望、疑虑与中间地带。
Cancer. 2020 Jun 1;126(11):2594-2596. doi: 10.1002/cncr.32810. Epub 2020 Mar 10.
3
Non-Small Cell Lung Cancer Responds to Osimertinib plus Savolitinib.非小细胞肺癌对奥希替尼加 savolitinib 有反应。
Cancer Discov. 2020 Apr;10(4):487. doi: 10.1158/2159-8290.CD-RW2020-025. Epub 2020 Feb 14.
4
Overcoming Osimertinib Resistance in Advanced Non-small Cell Lung Cancer.克服奥希替尼耐药性治疗晚期非小细胞肺癌。
Clin Oncol (R Coll Radiol). 2021 Oct;33(10):619-626. doi: 10.1016/j.clon.2021.07.015. Epub 2021 Aug 5.
5
A reply to "Comment on: 'Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer".对《关于“奥希替尼治疗表皮生长因子受体第20外显子突变阳性非小细胞肺癌患者”的评论》的回复
Lung Cancer. 2020 Oct;148:181. doi: 10.1016/j.lungcan.2020.07.031. Epub 2020 Aug 8.
6
Comment on: 'Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer'.关于《奥希替尼治疗表皮生长因子受体第20外显子突变阳性非小细胞肺癌患者》的评论
Lung Cancer. 2020 Oct;148:179-180. doi: 10.1016/j.lungcan.2020.06.001. Epub 2020 Jun 5.
7
Patient With Stage IV NSCLC and CNS Metastasis With EGFR Exon 18-25 Kinase Domain Duplication With Response to Osimertinib as a First-Line Therapy.IV期非小细胞肺癌伴中枢神经系统转移且表皮生长因子受体第18-25外显子激酶结构域重复的患者对奥希替尼一线治疗有反应
JCO Precis Oncol. 2021 Nov;5:88-92. doi: 10.1200/PO.20.00296.
8
Treatment of a NSCLC patient with osimertinib based on the detection of the EGFR T790M resistance mutation in cerebrospinal fluid.基于脑脊液中EGFR T790M耐药突变的检测，用奥希替尼治疗一名非小细胞肺癌患者。
Lung Cancer. 2017 Dec;114:111-112. doi: 10.1016/j.lungcan.2017.10.010. Epub 2017 Oct 28.
9
Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.奥希替尼治疗 EGFR 外显子 20 突变阳性非小细胞肺癌患者。
Lung Cancer. 2020 Mar;141:9-13. doi: 10.1016/j.lungcan.2019.12.013. Epub 2019 Dec 20.
10
Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC.连续液体活检揭示了EGFR驱动基因突变的动态变化，并表明EGFR扩增是NSCLC中对奥希替尼耐药的一种新机制。
Lung Cancer. 2017 Jun;108:238-241. doi: 10.1016/j.lungcan.2017.04.004. Epub 2017 Apr 10.

引用本文的文献

1
Heterogeneity and co-occurrence of resistance mechanisms in EGFR-TKI-induced NSCLC to SCLC transformation: a case report.表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）诱导的非小细胞肺癌向小细胞肺癌转化中耐药机制的异质性与共现：一例报告
AME Case Rep. 2025 Jun 18;9:85. doi: 10.21037/acr-24-67. eCollection 2025.
2
Comparative Survival Analysis of Anti-Angiogenic Agent Plus Immunochemotherapy in NSCLC Patients After Frontline EGFR-TKI Treatment: A Retrospective Cohort Study.一线表皮生长因子受体酪氨酸激酶抑制剂治疗后非小细胞肺癌患者中抗血管生成剂联合免疫化疗的生存比较分析：一项回顾性队列研究
Kaohsiung J Med Sci. 2025 Jul;41(7):e70023. doi: 10.1002/kjm2.70023. Epub 2025 Apr 28.
3
Possibilities of Overcoming Resistance to Osimertinib in NSCLC Patients with Mutations in the Gene.
克服非小细胞肺癌患者基因发生突变后对奥希替尼耐药的可能性。
Cancers (Basel). 2025 Feb 7;17(4):563. doi: 10.3390/cancers17040563.
4
Association of Pretreatment Albumin-bilirubin Grade With Hepatotoxicity and Efficacy in EGFR-TKIs Therapy for NSCLC.预处理白蛋白-胆红素分级与EGFR-TKIs治疗非小细胞肺癌的肝毒性和疗效的相关性
Cancer Diagn Progn. 2025 Jan 3;5(1):95-104. doi: 10.21873/cdp.10417. eCollection 2025 Jan-Feb.
5
Pericytes Modulate Third-Generation Tyrosine Kinase Inhibitor Sensitivity in EGFR-Mutated Lung Cancer Cells Through IL32-β5-Integrin Paracrine Signaling.周细胞通过IL32-β5-整合素旁分泌信号调节EGFR突变肺癌细胞对第三代酪氨酸激酶抑制剂的敏感性。
Adv Sci (Weinh). 2024 Dec;11(46):e2405130. doi: 10.1002/advs.202405130. Epub 2024 Oct 22.
6
Histologic transformation of non-small-cell lung cancer in response to tyrosine kinase inhibitors: Current knowledge of genetic changes and molecular mechanisms.非小细胞肺癌对酪氨酸激酶抑制剂的组织学转化：遗传改变和分子机制的最新知识。
Cancer Sci. 2024 Jul;115(7):2138-2146. doi: 10.1111/cas.16192. Epub 2024 May 27.
7
Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for Mutation-Positive Patients Treated with First-Line Osimertinib.一线奥希替尼治疗的 EGFR 突变阳性患者的后线治疗模式和结局的真实世界分析。
Curr Oncol. 2024 Apr 26;31(5):2427-2440. doi: 10.3390/curroncol31050182.
8
The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors.克服晚期非小细胞肺癌中奥希替尼耐药性的迫切需求：从联合策略到第四代酪氨酸激酶抑制剂
Front Oncol. 2024 Jan 9;13:1308460. doi: 10.3389/fonc.2023.1308460. eCollection 2023.
9
The Therapeutic Significance of HER3 in Non-small Cell Lung Cancer (NSCLC): A Review Study.HER3在非小细胞肺癌（NSCLC）中的治疗意义：一项综述研究。
Curr Med Chem. 2025;32(3):434-446. doi: 10.2174/0109298673269305231115102542.
10
[Impact of Folic Acid on the Resistance of Non-small Cell Lung Cancer Cells 
to Osimertinib by Regulating Methylation of DUSP1].[叶酸通过调节双特异性磷酸酶1的甲基化对非小细胞肺癌细胞奥希替尼耐药性的影响]
Zhongguo Fei Ai Za Zhi. 2024 Jan 2;26(12):881-888. doi: 10.3779/j.issn.1009-3419.2023.106.24.